Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Palisade Bio is a clinical-stage biopharmaceutical company developing next-generation prodrugs for inflammatory and fibrotic diseases. Its lead candidate, PALI-2108, is advancing into Phase 2 clinical trials for ulcerative colitis (UC) and Crohn's disease (CD). The company operates as a single segment focused on R&D.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| License Revenue | $500 | $500 | $0 |
| Total Operating Expenses | $12,198 | $22,946 | $5,153 |
| Research & Development | $7,400 | $13,797 | $2,625 |
| General & Administrative | $4,798 | $9,149 | $2,528 |
| Net Loss | $(10,574) | $(20,174) | $(5,014) |
| Cash and Cash Equivalents (as of June 30, 2026) |
$125,172 | ||
| Net Cash Used in Operating Activities | $(11,493) | $(4,150) | |
| Net Cash Provided by Financing Activities | $3,280 | $(254) |
Liquidity: As of June 30, 2026, the company held $125.2 million in cash, cash equivalents, and restricted cash. Management believes this is sufficient to fund operations through major clinical milestones expected in 2027 and 2028.
Material Changes vs. Prior Period
- Revenue: Recognized $0.5 million in license revenue in Q2 2026 from a milestone achievement under the Newsoara Co-Development Agreement, compared to $0 in the prior year period.
- Operating Expenses: Total operating expenses increased significantly by 329% ($9.4 million) for the quarter and 345% ($17.8 million) for the six months compared to the prior year.
- R&D: Increased primarily due to higher employee-related costs (including $4.0 million in stock-based compensation for the six months) and increased program expenses for PALI-2108 (clinical operations, CMC, and preclinical science).
- G&A: Increased due to higher employee-related costs (including $5.0 million in stock-based compensation for the six months), professional fees, and shareholder services.
- Net Loss: Net loss widened to $10.6 million for the quarter and $20.2 million for the six months, compared to $2.8 million and $5.0 million in the respective prior year periods.
- Other Income: Other income, net, increased to $1.1 million (quarter) and $2.3 million (six months) due to higher dividend income from money market funds following the October 2025 equity offering.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Phase 2 ASCENTRA-UC: FDA cleared the IND in June 2026. Enrollment is expected to begin in the second half of 2026, with primary efficacy results expected in the second half of 2027.
- Phase 2 ASCENTRA-CD: Plans to submit an IND in the second half of 2026, with primary efficacy results expected in early 2028.
- Capital Needs: Management expects to require additional financing beyond early 2028 to support potential Phase 3 trials and commercialization.
Material Risks and Contingencies:
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to the financial closing process, lack of segregation of duties, and journal entry controls. Remediation efforts are ongoing but the weakness remains as of June 30, 2026.
- Regulatory and Clinical Risk: Success depends entirely on the clinical development of PALI-2108. Risks include failure to meet endpoints, patient enrollment delays, and regulatory rejection.
- Supply Chain: Reliance on third-party manufacturers, including WuXi AppTec (designated as a "Chinese military company" by the U.S. DoD in June 2026), which may impact future federal procurement eligibility under the BIOSECURE Act.
- Liquidity: The company has a history of net losses and expects to continue incurring losses. Future profitability is uncertain.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $125.2 million cash balance against the projected burn rate for the upcoming Phase 2 trials.
- Internal Control Remediation: Monitor progress on remediation of the material weakness in financial reporting controls to ensure future financial statement reliability.
- Supply Chain Exposure: Assess the impact of the U.S. DoD designation of WuXi AppTec on the company's ability to secure federal funding or contracts for PALI-2108.
- Clinical Enrollment: Track the initiation and enrollment rates of the ASCENTRA-UC trial in the second half of 2026.
- Dilution Risk: Review the impact of outstanding warrants (including 37.8 million pre-funded warrants) and potential future equity financings on shareholder dilution.